NASDAQ: SRZN
Surrozen Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their SRZN stock forecasts and price targets.

Forecast return on equity

Is SRZN forecast to generate an efficient return?

Forecast return on assets

Is SRZN forecast to generate an efficient return on assets?

Company
-60.05%
Industry
96.33%
SRZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SRZN earnings per share forecast

What is SRZN's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$3.51
Avg 2 year Forecast
-$4.31
Avg 3 year Forecast
-$4.24

SRZN revenue forecast

What is SRZN's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$3.0M+85.78%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%

SRZN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SRZN$12.98N/AN/A
FATE$0.96$4.83+401.35%Buy
SEER$2.00N/AN/A
INO$2.05$4.50+119.51%Buy
ONCY$1.04$6.00+476.92%Strong Buy

Surrozen Stock Forecast FAQ

What is SRZN's earnings growth forecast for 2025-2027?

(NASDAQ: SRZN) Surrozen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.

Surrozen's earnings in 2025 is -$104,844,000.On average, 4 Wall Street analysts forecast SRZN's earnings for 2025 to be -$30,075,402, with the lowest SRZN earnings forecast at -$28,895,974, and the highest SRZN earnings forecast at -$30,959,973. On average, 4 Wall Street analysts forecast SRZN's earnings for 2026 to be -$36,982,253, with the lowest SRZN earnings forecast at -$40,655,964, and the highest SRZN earnings forecast at -$32,579,971.

In 2027, SRZN is forecast to generate -$36,370,254 in earnings, with the lowest earnings forecast at -$46,955,959 and the highest earnings forecast at -$24,569,978.

If you're new to stock investing, here's how to buy Surrozen stock.

What is SRZN's revenue growth forecast for 2025-2027?

(NASDAQ: SRZN) Surrozen's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.

Surrozen's revenue in 2025 is $1,638,000.On average, 4 Wall Street analysts forecast SRZN's revenue for 2025 to be $26,082,834, with the lowest SRZN revenue forecast at $16,517,128, and the highest SRZN revenue forecast at $35,999,968. On average, 4 Wall Street analysts forecast SRZN's revenue for 2026 to be $0, with the lowest SRZN revenue forecast at $0, and the highest SRZN revenue forecast at $0.

In 2027, SRZN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SRZN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SRZN) forecast ROA is -60.05%, which is lower than the forecast US Biotechnology industry average of 96.33%.

What is SRZN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SRZN) Surrozen's current Earnings Per Share (EPS) is -$22.34. On average, analysts forecast that SRZN's EPS will be -$3.51 for 2025, with the lowest EPS forecast at -$3.37, and the highest EPS forecast at -$3.61. On average, analysts forecast that SRZN's EPS will be -$4.31 for 2026, with the lowest EPS forecast at -$4.74, and the highest EPS forecast at -$3.80. In 2027, SRZN's EPS is forecast to hit -$4.24 (min: -$5.48, max: -$2.87).

What is SRZN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SRZN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.